Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
On July 11, 2021, the 2021 Cuban protests began with thousands of Cubans marching in the street as the single largest anti-government protest in Cuba since 1994. On July 14, Grand Master Zamora Fernández and Grand Secretary Carlos A. Pírez Benítez also addressed a letter to the whole of the Cuban people, the government, and all Cuban Freemasons. In this letter, they wrote that dialogue and tolerance were the most important ways to resolve any difference between parties that disagreed with each other. They desired human rights to be universally applied as codified in the Universal Declaration of Human Rights. They said that the events of the protests were foreseeable and entirely preventable; that it was not unordinary for a government to try and contain a protest, but that the Grand Lodge were disheartened by what they viewed as an excessive use of force and violence used by the government against the protestors. They stressed to the government that errors in governing a nation should never be approached with complacency. They wrote that July 14 was a special day of solemn remembrance in the history of Cuban Freemasonry, as it was that day, many years earlier, when the Grand Lodge of Cuba returned to their use of the motto of Liberty, Equality, and Fraternity. They wrote that all people are equal before the law, and that the Grand Lodge of Cuba stood alongside the people of Cuba, and advocated for peace, harmony and justice.
== Mechanism of action == The primary mechanism of action by PDRN is the adenosine A2A receptor pathway, which is activated following enzymatic degradation of the deoxyribonucleotide polymers. Adenosine acts the primary ligand which binds to the G protein-coupled receptor A2A leading to an increase in intracellular cyclic AMP (cAMP) levels. This secondary messenger activates protein kinase A (PKA) acting as a signaling cascade of several pathways downstream.Thus, enhacing tissue repair through upregulation of PI3K/Akt and vascular endothelial growth factor (VEGF). The activation of the A2A pathway is observed to be conserved across various PDRN sources, yet it activates different downstream pathways depending on the type of tissue and injury. Additionally, PDRN contributes to the salvage pathway, which is a metabolic mechanism that supports nucleotide synthesis for processes like DNA replication and celullar proliferation. For injuries needing faster regeneration, this nucleoside input is essential, highlighling the importance of both signaling and metabolic pathways for optimal tissue repair.
Acetalated dextran is a biodegradable polymer based on dextran that has acetal modified hydroxyl groups. After synthesis, the hydrophilic polysaccharide dextran is rendered insoluble in water, but soluble in organic solvents. This allows it to be processed in the same manner as many polyesters, like poly(lactic-co-glycolic acid), through processes like solvent evaporation and emulsion. Acetalated dextran is structurally different from acetylated dextran.
Sources: en.wikipedia.org
=== 2008–2009: Beginnings === Riff Raff started rapping in 2005, making homemade CDs of his rapping over other artists' beats, and passing them out at various malls in the Greater Houston Area including Katy Mills Mall. He credited his early influences being Texas veteran rappers Devin the Dude and Paul Wall. Riff Raff took advantage of social media on Myspace, YouTube and WorldStarHipHop in late 2008, releasing songs, freestyle-videos, and sketch clips, which showcased his talent as slapstick and performance art. He did this with the help of his first talent manager, DB da Boss, whose studio provided recording and video services. DB spoke with LA Weekly about the rapper, saying "He was very driven, very ambitious. You couldn't deny his work ethic", going on to say, "Underneath that shell is a very intelligent man." He looked up to Northside Houston rappers from label Swishahouse, who were blowing up around that time, including Paul Wall, Chamillionaire and Slim Thug. He began doing his hair up in braids popular among "Northsiders" like Slim Thug and shopping for bling at TV Jewelry, a store co-owned by Paul Wall and charismatic Vietnamese immigrant "TV" Johnny Dang, from whom Riff Raff also purchased gold grills. Like many other artists from Houston, Riff Raff also spent much of his time selling CDs at colleges and malls, occasionally alongside other local talent such at Fat Tony and Freestyle Bully. In an effort to get on television he went on many auditions, including for a part in a peanut butter commercial intended for a teenager.
Jelleine is a family of peptides, isolated from the royal jelly of Apis mellifera iberiensis, a subspecies of the honey bee. This new family has the potential to be used in the development of new drugs.
In this application, Ion-exchange resins are used to replace the magnesium and calcium ions found in hard water with sodium ions. When the resin is fresh, it contains sodium ions at its active sites. When in contact with a solution containing magnesium and calcium ions (but a low concentration of sodium ions), the magnesium and calcium ions preferentially migrate out of solution to the active sites on the resin, being replaced in solution by sodium ions. This process reaches equilibrium with a much lower concentration of magnesium and calcium ions in solution than was started with.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.